S&P 500   5,094.79 (+0.12%)
DOW   39,194.22 (+0.16%)
QQQ   437.36 (+0.13%)
AAPL   182.03 (-0.27%)
MSFT   411.05 (+0.17%)
META   481.98 (-0.42%)
GOOGL   140.78 (-2.21%)
AMZN   175.23 (+0.14%)
TSLA   195.01 (+1.58%)
NVDA   801.41 (+1.68%)
NIO   5.64 (+4.44%)
AMD   178.01 (+0.84%)
BABA   76.26 (+0.39%)
T   16.81 (+0.06%)
F   12.14 (+0.00%)
MU   90.15 (+4.83%)
CGC   3.43 (+2.08%)
GE   154.14 (+0.53%)
DIS   107.88 (+0.13%)
AMC   4.47 (+0.68%)
PFE   27.47 (-1.04%)
PYPL   59.07 (-0.15%)
XOM   103.60 (-0.23%)
S&P 500   5,094.79 (+0.12%)
DOW   39,194.22 (+0.16%)
QQQ   437.36 (+0.13%)
AAPL   182.03 (-0.27%)
MSFT   411.05 (+0.17%)
META   481.98 (-0.42%)
GOOGL   140.78 (-2.21%)
AMZN   175.23 (+0.14%)
TSLA   195.01 (+1.58%)
NVDA   801.41 (+1.68%)
NIO   5.64 (+4.44%)
AMD   178.01 (+0.84%)
BABA   76.26 (+0.39%)
T   16.81 (+0.06%)
F   12.14 (+0.00%)
MU   90.15 (+4.83%)
CGC   3.43 (+2.08%)
GE   154.14 (+0.53%)
DIS   107.88 (+0.13%)
AMC   4.47 (+0.68%)
PFE   27.47 (-1.04%)
PYPL   59.07 (-0.15%)
XOM   103.60 (-0.23%)
S&P 500   5,094.79 (+0.12%)
DOW   39,194.22 (+0.16%)
QQQ   437.36 (+0.13%)
AAPL   182.03 (-0.27%)
MSFT   411.05 (+0.17%)
META   481.98 (-0.42%)
GOOGL   140.78 (-2.21%)
AMZN   175.23 (+0.14%)
TSLA   195.01 (+1.58%)
NVDA   801.41 (+1.68%)
NIO   5.64 (+4.44%)
AMD   178.01 (+0.84%)
BABA   76.26 (+0.39%)
T   16.81 (+0.06%)
F   12.14 (+0.00%)
MU   90.15 (+4.83%)
CGC   3.43 (+2.08%)
GE   154.14 (+0.53%)
DIS   107.88 (+0.13%)
AMC   4.47 (+0.68%)
PFE   27.47 (-1.04%)
PYPL   59.07 (-0.15%)
XOM   103.60 (-0.23%)
S&P 500   5,094.79 (+0.12%)
DOW   39,194.22 (+0.16%)
QQQ   437.36 (+0.13%)
AAPL   182.03 (-0.27%)
MSFT   411.05 (+0.17%)
META   481.98 (-0.42%)
GOOGL   140.78 (-2.21%)
AMZN   175.23 (+0.14%)
TSLA   195.01 (+1.58%)
NVDA   801.41 (+1.68%)
NIO   5.64 (+4.44%)
AMD   178.01 (+0.84%)
BABA   76.26 (+0.39%)
T   16.81 (+0.06%)
F   12.14 (+0.00%)
MU   90.15 (+4.83%)
CGC   3.43 (+2.08%)
GE   154.14 (+0.53%)
DIS   107.88 (+0.13%)
AMC   4.47 (+0.68%)
PFE   27.47 (-1.04%)
PYPL   59.07 (-0.15%)
XOM   103.60 (-0.23%)

Ultragenyx Pharmaceutical (RARE) Stock Price, News & Analysis

$50.49
+1.01 (+2.04%)
(As of 09:34 AM ET)
Today's Range
$49.43
$50.49
50-Day Range
$43.02
$49.78
52-Week Range
$31.52
$54.98
Volume
4,622 shs
Average Volume
768,273 shs
Market Capitalization
$4.16 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$92.20

Ultragenyx Pharmaceutical MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
82.6% Upside
$92.20 Price Target
Short Interest
Healthy
4.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.28
Upright™ Environmental Score
News Sentiment
0.39mentions of Ultragenyx Pharmaceutical in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.41) to ($5.05) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.71 out of 5 stars

Medical Sector

58th out of 935 stocks

Pharmaceutical Preparations Industry

20th out of 429 stocks


RARE stock logo

About Ultragenyx Pharmaceutical Stock (NASDAQ:RARE)

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

RARE Stock Price History

RARE Stock News Headlines

Blue Chips And Billionaires Quietly Investing In "The New Oil"
They're as essential to the tech and AI revolutions as oil was to the industrial revolution. Known as rare earth elements or REEs, these relatively unheard of commodities are essential to semiconductor chips, renewable energy, electric vehicles, and more.
Blue Chips And Billionaires Quietly Investing In "The New Oil"
They're as essential to the tech and AI revolutions as oil was to the industrial revolution. Known as rare earth elements or REEs, these relatively unheard of commodities are essential to semiconductor chips, renewable energy, electric vehicles, and more.
Barclays Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
Q4 2023 Ultragenyx Pharmaceutical Inc Earnings Call
Recap: Ultragenyx Pharmaceutical Q4 Earnings
Ultragenyx Pharmaceutical Inc Q4 Loss decreases, beats estimates
Preview: Ultragenyx Pharmaceutical's Earnings
See More Headlines
Receive RARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
2/26/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RARE
Employees
1,276
Year Founded
2010

Price Target and Rating

Average Stock Price Target
$92.20
High Stock Price Target
$133.00
Low Stock Price Target
$48.00
Potential Upside/Downside
+82.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$-606,640,000.00
Net Margins
-139.70%
Pretax Margin
-140.12%

Debt

Sales & Book Value

Annual Sales
$434.25 million
Book Value
$3.35 per share

Miscellaneous

Free Float
76,737,000
Market Cap
$4.16 billion
Optionable
Optionable
Beta
0.66

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives















RARE Stock Analysis - Frequently Asked Questions

Should I buy or sell Ultragenyx Pharmaceutical stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RARE shares.
View RARE analyst ratings
or view top-rated stocks.

What is Ultragenyx Pharmaceutical's stock price target for 2024?

9 Wall Street research analysts have issued 1 year price objectives for Ultragenyx Pharmaceutical's stock. Their RARE share price targets range from $48.00 to $133.00. On average, they predict the company's share price to reach $92.20 in the next year. This suggests a possible upside of 82.6% from the stock's current price.
View analysts price targets for RARE
or view top-rated stocks among Wall Street analysts.

How have RARE shares performed in 2024?

Ultragenyx Pharmaceutical's stock was trading at $47.82 at the beginning of 2024. Since then, RARE stock has increased by 5.6% and is now trading at $50.49.
View the best growth stocks for 2024 here
.

Are investors shorting Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical saw a decline in short interest in the month of January. As of January 31st, there was short interest totaling 3,410,000 shares, a decline of 17.2% from the January 15th total of 4,120,000 shares. Based on an average daily trading volume, of 801,200 shares, the short-interest ratio is presently 4.3 days.
View Ultragenyx Pharmaceutical's Short Interest
.

When is Ultragenyx Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our RARE earnings forecast
.

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) posted its quarterly earnings data on Thursday, February, 15th. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.65) by $0.13. The biopharmaceutical company earned $127.39 million during the quarter, compared to analysts' expectations of $119.38 million. Ultragenyx Pharmaceutical had a negative trailing twelve-month return on equity of 369.54% and a negative net margin of 139.70%. The business's revenue for the quarter was up 23.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($2.16) EPS.

What guidance has Ultragenyx Pharmaceutical issued on next quarter's earnings?

Ultragenyx Pharmaceutical issued an update on its FY 2024 earnings guidance on Monday, January, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $500.0 million-$530.0 million, compared to the consensus revenue estimate of $523.9 million.

What is Emil D. Kakkis' approval rating as Ultragenyx Pharmaceutical's CEO?

41 employees have rated Ultragenyx Pharmaceutical Chief Executive Officer Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM).

Who are Ultragenyx Pharmaceutical's major shareholders?

Ultragenyx Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.56%), RTW Investments LP (8.39%), Sands Capital Management LLC (5.02%), Price T Rowe Associates Inc. MD (4.20%), Federated Hermes Inc. (2.98%) and Clearbridge Investments LLC (2.90%). Insiders that own company stock include Camille L Bedrosian, Corazon (Corsee) D Sanders, Dennis Karl Huang, Emil D Kakkis, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, S Robson Walton, Theodore Alan Huizenga and Thomas Richard Kassberg.
View institutional ownership trends
.

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RARE) was last updated on 2/26/2024 by MarketBeat.com Staff